|
MechanismIL-2Rβ inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FB102 after multiple dose administration in participants with celiac disease.
/ Not yet recruitingPhase 1 A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FB102 after single and multiple ascending dose administrations in healthy participants
100 Clinical Results associated with Forte Biosciences Australia Pty Ltd.
0 Patents (Medical) associated with Forte Biosciences Australia Pty Ltd.
100 Deals associated with Forte Biosciences Australia Pty Ltd.
100 Translational Medicine associated with Forte Biosciences Australia Pty Ltd.